§ Same category · GLP-1 / metabolic peptides
Orforglipron vs Retatrutide
Side-by-side price comparison across every tracked vendor. Updated every 4–6 hours.
Pepticker may earn affiliate commissions (typically 5-20%) from linked vendors. See our Affiliate Disclosure.
Orforglipron
0
vendors tracked
Retatrutide
6
vendors tracked
from $2.60/mg
Orforglipron
Oral small-molecule GLP-1 agonist
No current listings at 0.024mg.
Retatrutide
Triple GCG/GIP/GLP-1 agonist
B
Operational$49.99
$5.00/mg
In stock◎ Best $/mg
Watch
$103.99
$10.40/mg
In stock▲ 108.0% vs best
Watch
$129.99
$13.00/mg
In stock▲ 160.0% vs best
| Vendor | Grade | Risk | Price | $/mg | Trend | Stock | |
|---|---|---|---|---|---|---|---|
| Welli Labs US | B | Operational | $49.99 ◎ Best $/mg | $5.00 | In stock | Buy with code → | |
| Australian Peptide Store AU | B- | Watch | $103.99 ▲ 108.0% | $10.40 | In stock | Visit → | |
| Felix Chemical Supply US | B- | Watch | $129.99 ▲ 160.0% | $13.00 | In stock | Visit → |
Sort:
Last crawl 2026-11-12Sort:
2026-11-12About Orforglipron
An oral non-peptide GLP-1 receptor agonist in Phase 3 for obesity and type-2 diabetes. Typically sold as capsules in research-compound form.
About Retatrutide
An investigational triple-agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 clinical trials for obesity are ongoing; research-compound version is sold via research-chemical vendors.